$242 Million is the total value of Endurant Capital Management LP's 73 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 51.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| STJ | Buy | ST JUDE MED INC | $9,685,000 | +11.3% | 120,777 | +10.8% | 4.00% | +24.1% |
| BDX | Buy | BECTON DICKINSON & CO | $7,781,000 | +2181.8% | 47,000 | +2373.7% | 3.22% | +2451.6% |
| BSX | Buy | BOSTON SCIENTIFIC CORP | $7,185,000 | +16.9% | 332,198 | +28.6% | 2.97% | +30.3% |
| ESRX | Buy | EXPRESS SCRIPTS HLDG CO | $6,613,000 | +22.0% | 96,127 | +25.1% | 2.73% | +36.0% |
| ABC | Buy | AMERISOURCEBERGEN CORP | $6,532,000 | +15.6% | 83,540 | +19.4% | 2.70% | +28.8% |
| HRC | Buy | HILL ROM HLDGS INC | $6,250,000 | +425.2% | 111,335 | +479.9% | 2.58% | +485.7% |
| BCR | Buy | BARD C R INC | $5,533,000 | +55.9% | 24,627 | +55.6% | 2.29% | +73.7% |
| DVA | Buy | DAVITA INC | $5,395,000 | +2.9% | 84,039 | +5.9% | 2.23% | +14.7% |
| WMGI | Buy | WRIGHT MED GROUP N V | $5,280,000 | +13.5% | 229,777 | +21.2% | 2.18% | +26.6% |
| TMO | Buy | THERMO FISHER SCIENTIFIC INC | $5,148,000 | +56.5% | 36,486 | +76.4% | 2.13% | +74.5% |
| PFE | New | PFIZER INC | $4,518,000 | – | 139,100 | +100.0% | 1.87% | – |
| CELG | Buy | CELGENE CORP | $4,107,000 | +17.3% | 35,480 | +6.0% | 1.70% | +30.8% |
| ANTM | Buy | ANTHEM INC | $4,040,000 | +311.8% | 28,100 | +258.9% | 1.67% | +358.5% |
| CVS | Buy | CVS HEALTH CORP | $3,669,000 | +38.9% | 46,500 | +56.7% | 1.52% | +54.9% |
| EVHC | New | ENVISION HEALTHCARE CORP | $3,538,000 | – | 55,900 | +100.0% | 1.46% | – |
| CAH | Buy | CARDINAL HEALTH INC | $3,534,000 | +399.9% | 49,100 | +439.6% | 1.46% | +457.3% |
| GSK | New | GLAXOSMITHKLINE PLCsponsored adr | $3,327,000 | – | 86,400 | +100.0% | 1.38% | – |
| HSIC | New | SCHEIN HENRY INC | $3,216,000 | – | 21,200 | +100.0% | 1.33% | – |
| PEN | Buy | PENUMBRA INC | $3,158,000 | +477.3% | 49,500 | +587.5% | 1.30% | +542.9% |
| LLY | New | LILLY ELI & CO | $2,802,000 | – | 38,100 | +100.0% | 1.16% | – |
| BBH | Buy | VANECK VECTORS ETF TRbiotech etf | $2,652,000 | +274.0% | 24,650 | +300.8% | 1.10% | +316.7% |
| AERI | Buy | AERIE PHARMACEUTICALS INC | $2,371,000 | +49.5% | 62,630 | +49.0% | 0.98% | +66.7% |
| New | FLUIDIGM CORP DELnote 2.750% 2/0 | $2,183,000 | – | 3,161,000 | +100.0% | 0.90% | – | |
| INCY | Buy | INCYTE CORP | $2,025,000 | +329.9% | 20,200 | +304.0% | 0.84% | +378.3% |
| JAZZ | New | JAZZ PHARMACEUTICALS PLC | $1,788,000 | – | 16,400 | +100.0% | 0.74% | – |
| CTLT | Buy | CATALENT INC | $1,591,000 | +33.8% | 59,008 | +28.3% | 0.66% | +49.0% |
| ACHC | New | ACADIA HEALTHCARE COMPANY IN | $1,483,000 | – | 44,800 | +100.0% | 0.61% | – |
| FOLD | Buy | AMICUS THERAPEUTICS INC | $1,120,000 | +253.3% | 225,300 | +425.2% | 0.46% | +295.7% |
| STE | Buy | STERIS PLC | $1,119,000 | +61.2% | 16,600 | +74.7% | 0.46% | +79.8% |
| EW | New | EDWARDS LIFESCIENCES CORP | $993,000 | – | 10,600 | +100.0% | 0.41% | – |
| MDCO | Buy | MEDICINES CO | $927,000 | +19.3% | 27,300 | +32.5% | 0.38% | +33.0% |
| EXEL | Buy | EXELIXIS INC | $908,000 | +41.2% | 60,870 | +21.0% | 0.38% | +57.6% |
| CLVS | Buy | CLOVIS ONCOLOGY INC | $817,000 | +173.2% | 18,400 | +121.7% | 0.34% | +204.5% |
| PPH | New | VANECK VECTORS ETF TRpharmaceutical e | $819,000 | – | 15,600 | +100.0% | 0.34% | – |
| REGN | New | REGENERON PHARMACEUTICALS | $808,000 | – | 2,200 | +100.0% | 0.33% | – |
| ONCE | Buy | SPARK THERAPEUTICS INC | $739,000 | +112.4% | 14,800 | +155.2% | 0.30% | +136.4% |
| OCRX | Buy | OCERA THERAPEUTICS INC | $476,000 | +75.0% | 226,442 | +119.5% | 0.20% | +95.0% |
| ARRY | Buy | ARRAY BIOPHARMA INC | $247,000 | +263.2% | 28,100 | +181.0% | 0.10% | +308.0% |
| SRPT | New | SAREPTA THERAPEUTICS INC | $230,000 | – | 8,400 | +100.0% | 0.10% | – |
| DVAX | New | DYNAVAX TECHNOLOGIES CORP | $224,000 | – | 56,800 | +100.0% | 0.09% | – |
| GLYC | New | GLYCOMIMETICS INC | $88,000 | – | 14,500 | +100.0% | 0.04% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LABORATORY CORP AMER HLDGS | 31 | Q2 2023 | 8.7% |
| ELEVANCE HEALTH INC | 29 | Q3 2023 | 8.8% |
| BECTON DICKINSON & CO | 28 | Q2 2023 | 9.8% |
| MCKESSON CORP | 27 | Q1 2023 | 4.4% |
| CENCORA INC | 26 | Q3 2023 | 5.9% |
| HOLOGIC INC | 24 | Q3 2023 | 7.5% |
| JOHNSON & JOHNSON | 24 | Q4 2021 | 5.5% |
| ZIMMER HLDGS INC | 23 | Q3 2023 | 7.5% |
| BOSTON SCIENTIFIC CORP | 22 | Q3 2023 | 5.5% |
| DAVITA INC | 22 | Q1 2021 | 4.9% |
View Endurant Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| AZIYO BIOLOGICS, INC. | March 21, 2023 | 576,253 | 4.9% |
| Oxford Immunotec Global PLCSold out | February 17, 2021 | 0 | 0.0% |
View Endurant Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-07 |
| SC 13D/A | 2024-04-10 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13D/A | 2023-09-08 |
| 13F-HR | 2023-08-14 |
| 3/A | 2023-05-24 |
| 13F-HR | 2023-05-15 |
| 3 | 2023-05-15 |
| SC 13D | 2023-05-15 |
View Endurant Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.